Awards & Advancement

Emma Walmsley to succeed Andrew Witty as CEO of GlaxoSmithKline

Wednesday, September 21, 2016

GSK has announced that Emma Walmsley, currently chief executive officer (CEO) of GSK’s Consumer Healthcare division, has been appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO when he retires on March 31, 2017. Walmsley will join the GSK board of directors January 2017.

[Read More]

Pediatric Cancer Foundation to honor Congressmen McCaul & Van Hollen

Wednesday, September 21, 2016

Congressman Michael Mccaul and Congressman Chris Van Hollen to be honored at the 3rd Annual Golden Toast. The Golden Toast represents bipartisan politics at its finest. It is an evening when members of Congress from both sides of the aisle demonstrate a commitment to some of the most vulnerable members of society—children who are fighting cancer. In an election season marked by divisiveness, the Golden Toast is a visible reminder that our elected officials can put aside disagreements to accomplish meaningful change and advance life-saving research. 

[Read More]

EMD Serono appoints Craig Millian SVP, Neurology And Immunology

Tuesday, September 20, 2016

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, has announced the appointment of Craig Millian as senior vice president, Neurology and Immunology. Millian most recently served as senior vice president, head of U.S. Fertility and Endocrinology at EMD Serono. In his new role, he will lead the strategic direction of the company’s U.S. Neurology and Immunology franchise.

[Read More]

Exco InTouch appoints Steve Powell as chief operating officer

Wednesday, September 14, 2016

Exco InTouch, a provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, has appointed Steve Powell as the company’s chief operating officer and president. In this newly created position, Powell will be responsible for all aspects of Exco InTouch’s operational delivery including services and technology.  

[Read More]

Pfizer appoints chief scientific officer for Neuroscience Research

Wednesday, September 14, 2016

Pfizer has announced that Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, will become chief scientific officer of the Neuroscience Research Unit and senior vice president, effective September 16. Dr. Isacson is a professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report directly to Mikael Dolsten, president of Worldwide Research and Development.

[Read More]